No! As stated only given if listing develops and will be issued pre consolidation. Also double checked with previous prospectus and the number of shares have increased only by roughly 1/2 million. Nothing I can see about patient numbers but the only inkling is projected revenue for 2020 calendar year of 11M. All they did though was double 2019 revenue.
My feeling is this will happen! I say this based on lessons hopefully learnt previously by GMV. why would you only consolidate by 18 and put such a premium if you weren’t confident. We really are backed in a corner if this doesn’t go through. I guess it’s all or nothing. One thing though about Yacov he could have easily screwed us by consolidation at 200 or more to 1 and issues shares to himself at minimal or no price but he didn’t. Anyway let’s list first. If we are able to list then who’s to say with exponential increase in patient number as observed we don’t see 8-12 dollars. You forget these potential investors haven’t been over promised and under delivered to yet.
GMV Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
